PA
NNVC icon

Parallel Advisors’s NanoViricides NNVC Stock Holding History

Parallel Advisors’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-157
Closed -$236 – 3588
2024
Q3 		$236 Hold
157
– – ﹤0.01% 3283
2024
Q2 		$270 Buy
+157
New +$280 ﹤0.01% 3166

Other funds holding NNVC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Parallel Advisors's NNVC Position: Q4 2024 in Review

Parallel Advisors sold out of NanoViricides (NNVC) in Q4 2024, closing a stake of 157 shares — an estimated $236 sold.

Parallel Advisors first reported a position in NNVC in Q2 2024 and held it in 2 quarters. The position peaked at $270 in Q2 2024. 36 funds tracked by Wall St. Rank hold NNVC as of Q4 2024.

  • Parallel Advisors reported no remaining NanoViricides position as of Q4 2024 after selling out during the quarter.
  • Parallel Advisors sold 157 NanoViricides shares in Q4 2024, an estimated $236.
  • Parallel Advisors first reported a position in NanoViricides in Q2 2024 and held it in 2 quarters.
  • Parallel Advisors's NanoViricides position peaked at $270 in Q2 2024.
  • 36 funds tracked by Wall St. Rank held NanoViricides as of Q4 2024.

Based on Parallel Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.